Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab. (ClinicalTrials.gov number, NCT00078572 ClinicalTrials.gov.).